Europe’s Pharmaceutical Strategy in a Changing Global Order: Germany and France Push for Resilience and Competitiveness | iPharmaCenter
- Badari Andukuri
- May 22
- 3 min read
Updated: May 24
As the global geopolitical landscape shifts, Europe is reassessing its position in the pharmaceutical sector, aiming to protect its strategic autonomy while maintaining global competitiveness. A joint declaration by Germany and France highlights a renewed commitment to strengthening Europe’s pharmaceutical industry amid rising international pressures and structural challenges.
What Makes Europe a Key Pharmaceutical Market?
With a population of nearly 520 million across the European Union (EU) and European Economic Area (EEA), and near-universal healthcare access, Europe represents a major pharmaceutical market, accounting for approximately 25% of global drug sales. However, this position is increasingly under threat.
Why Is Europe’s Pharmaceutical Competitiveness Under Pressure?
Europe’s pharmaceutical ecosystem is facing mounting challenges from multiple fronts. Stricter regulatory frameworks, including environmental standards and occupational safety requirements, have increased operational complexity for manufacturers. At the same time, countries such as India and China are rapidly expanding their pharmaceutical capabilities, offering cost advantages and attracting global investments.
In parallel, years of offshoring have weakened Europe’s domestic manufacturing base, raising concerns about industrial sovereignty and supply chain vulnerabilities. These issues have been further amplified by recent geopolitical tensions and policy shifts, including the United States’ Most Favoured Nation (MFN) pricing approach, which could affect both access to innovative therapies and the export potential of European pharmaceutical companies.
How Are Geopolitical Developments Impacting Europe’s Pharma Sector?
Global political tensions are beginning to influence pharmaceutical markets.
Policies such as the United States Most Favoured Nation pricing approach may affect Europe’s access to innovative medicines and could also impact export potential for European pharmaceutical companies.
What Are Germany and France Proposing?
Germany and France are calling for a unified European response focused on:
Strengthening supply chain security and domestic production.
Improving the global competitiveness of Europe’s pharmaceutical sector.
Supporting innovation while maintaining regulatory and environmental standards.
Their joint declaration emphasizes coordinated action across the European Union.
What Are the Short-Term Priorities?
In the short term, European policy makers are expected to introduce incentive-driven measures to stabilize the pharmaceutical market and ensure access to medicines. These may include financial incentives, targeted support for critical supply chains, and regulatory adjustments to improve market access.
What Are the Long-Term Strategic Reforms?
Long-term resilience will depend on structural reforms already proposed or under development, including:
The EU Pharmaceutical Package to modernize regulatory systems.
The Biotech Act to promote research, innovation, and investment.
The Critical Medicines Act to secure supply chains for essential drugs.
These initiatives aim to make Europe more attractive for pharmaceutical investment and innovation.
Why Is Franco-German Cooperation Important?
Germany and France have historically played a leading role in shaping European health and pharmaceutical policy. Their collaboration reflects a broader effort to drive unified action across the EU and strengthen the region’s strategic autonomy in healthcare.
What Does This Mean for the Future of Europe’s Pharma Industry?
In an era defined by geopolitical uncertainty, supply chain disruptions, and intensifying global competition, Europe’s response will be critical. The Franco-German declaration reflects a strategic shift toward resilience, sovereignty, and innovation, key pillars that will shape the future of the European pharmaceutical industry.
As Europe adapts to this changing global order, its ability to implement coordinated policies and sustain innovation will determine whether it remains a leading force in the global pharmaceutical landscape.
Comments